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Introduction engue fever (DF) and the more severe forms of the disease, i.e., dengue hemorrhagic fever (DHF) and dengue shock syndrome, occur in tropical and subtropical regions globally through infection by one or more of four viral serotypes (dengue serotypes 1 -4).' Dengue virus is a member of the genus Fiavivirus. family FlaviWridac, that is transmitted in a cycle that primarily involves humans and mosquito vectors, most significantly Aedes aegypti in developing urban regions and A. aegypti as well as Aedes albopictus in semiurban areas and rural regions,'"''The prevalence of dengue virus is now comparable to that of malaria, making DF the most significant mosquito-bome wal disease, threatening two-iifths of the world's human population.*^'^ It is estimated that 50 to 100 million people are affected annually with DF and 300,000 with DHF/dengue shock syndrome.' ' Dengue ylrus surveillance and DF/DHF diagnoses are problematic. Symptoms are usually nonspecific, and serological analyses or virus isolation can take 1 week or more.''^'Â ntibody cross-reaction occurs across the Flaviviridae family, creating ambiguity.'°" To augment clinical laboratory diagnostic capability, dengue virus reverse transcription (RT)-polymerase chain reaction (PCR) assays have been developed for use with laboratory-based instrumentation.'^"'" In areas in which clinicai laboratory diagnostics are not available, field surveillance is an essential element in achieving timely assessments of transmission risk and time-critical implementation of appropriate tnosquito control measures and clinical responses in a potential outbreak situation. Rapid identification of circulating virus serotypes and causative serotypes in prexious outbreaks is fundamental to risk assessment for DHF.
Given the expansion of expeditionary operations worldwide. U,S. Armed Forces are at risk for acquiring a variety of infections, including dengue. After World War II. a dengue pandemic in Southeast Asia marked expanded emergence of the virus, with epidemics caused by multiple serotypes. ' With no licensed vaccine available. DF and other febrile diseases remain a threat to U.S. military operations, as obsen'ed throughout the history of conflict'^ and most recently during Operation Restore Hope.^" This threat drives the need for improved far-forward surveillance and rapid diagnosis of febrile illnesses. In the past several years, PCR has been shown to be a military field-worthy technique for rapid identification of biological agents.^'"^^ In this work, we describe a PCRbased assay system for rapid, sensitive, specific screening of dengue virus and serotype identification in mosquito vectors and human sera, using deployable instrumentation. Louis encephalitis virus-type strain genomic sequences were aiigned and \1sually evaluated to validate heterology wilh universal primer and probe sequences (GenBank accession numbers X03700/K02749, M18370, M12294/M10103. and AF242895, respectively). Universal primer and probe sequences can be requested through the corresponding author. Serotypespecific primer and probe sequences were obtained from the literature (DEN-l,'^ DV-2,'3 DEN-3,'2 and DEN-4'2|. and heterology was validated as described above. All probes reported here are dual fluorogenic labels designed with a 5' reporter dye. 6-carboxytluorescein. and a 3' quencher dye, 6-carboxytetramethylrhodamine,''^'' Universal and serotype-specific primers and probes sequence heterology with genomic sequences of closely related species through diverse genera was validated by BLAST database search (BLAST, Madison, Wisconsin).^' Melting temperatures were quantified and the absence of significant primer dimerizations and secondary structure (hairpin) formations was confirmed with PrimerExpress software (PE Applied Biosystems. Foster City. California). Primers and probes were synthesized and quality control was conducted commercially (Synthetic Genetics, San Diego, California). Assays were designated DU-JCM. DEN-1, DEN-2, DEN-3, and DEN-4, respectively.
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Flavivirus Reference Strains
To optimize RT-PCR assay sensitivity and specificity, nucleic acid extracts of reference strains of dengue virus serotypes and other flaviviruses were obtained from the Southwest Foundation for Biomedical Research (San Antonio, Texas) and the Center for Tropical Diseases. University of Texas Health Science Center (Galveston. Texas). Species and strain nucleic acid extracts included dengue 1 (Hawaii. Mochizuki. and 106), dengue 2 (SI6803, NGC, VEN2, 131. Mara-3. Mex44. ig2913. and 102954). dengue 3 (CH53489. H87. and 53402). dengue 4 (H241. Dakar NC599. and VEN4). yellow fever (Asibe. TVP834, and TVP8249). Japanese encephalitis (JKT9092, PhAnlO91, and JKT8442). West Nile vims (Crow 397-99. TVP3545, and TVP8345). and St, Louis encephalitis (Fort Washington, TVP8314, TVP8344. and LA2001).
Assay Optimization
Relative sensitivity levels of each assay were optimized with six logarithmic dilutions of each dengue serotype. prepared by diluting nucieic acid extracts 1:10 in RT-PCR-grade water with 2 U of RNase inhibitor. The specificity of each assay was tested with undiluted samples and four logarithmic dilutions of each heterologous dengue serotype and other flaviviruses, prepared by dilution as described above.
Mosquito Panels
To validate RT-PCR assay in vitro sensitivity and specificity, mosquito panels were prepared at the Virology Division. U.S. Army Medical Research Institute for Infectious Disease (USAM-RIID") (Fort Detrick, Maryland), One-to 6-day-old. adult, female, A. aegypti mosquitoes were inoculated intrathoracically^" with one of the following viruses: dengue 1 (Hawaii), dengue 2 (S16803). dengue 3 (CH53489). dengue 4 (H241). yellow fever (Asibe). West Nile (Crow 397-99), or St, Louis encephalitis (Fort Washington). Mosquitoes were held in cardboard cages, provided with a carbohydrate source (either apple slices or a gauze pad soaked in a 10% sucrose solution) and a water-soaked cotton pledget, and held at 26T for 7 days. Mosquitoes were then killed by exposure to -20°C for 5 to 10 minutes, and one to six legs were removed for analyses. Legs were triturated in grinding diluent (10% heat-inactivated fetal bovine serum in medium 199 with Earle's salts, NaHCO^. and antibiotics) and tested for the presence of virus by plaque assay on LLC-MK-2 cells. One virus-inoculated or one unexposed mosquito body was added to each pool of uninfected mosquitoes. These were placed in sterile, 1.5-mL. Eppendorf tubes and triturated in 750 /xLofTRIzol-LS (Life Technologies, Rock\111e. Maryland), A panel was established, labeled under code at USAMRIIE), and shipped on dry ice to the Epidemiological Surveillance Diiision. U.S. Air Force Institute for Environment. Satety. and Occupational Health Analysis. Brooks Air Force Base (San Antonio. Texas), for nucleic acid extraction and blind RT-PCR analyses (Table I) ,
Clinical Specimens
Human blood specimens were collected during a DF epidemic in Tegucigalpa, Honduras, in February 2002. by the U.S. Army Center for Health Promotion and Preventative Medicine-West in collaboration with the Houduran Ministry of Health (HMOH). from a total of 39 febrile and convalescent patients 0 to 5 days after the onset of fever and after defervescence, respectively. The HMOH confirmed the presence of dengue virus by serological testing (Table II) . and tbe specimens were archived at -20°C. Sera were subsequently thawed, and 500-;U.L aliquots of each specimen were prepared and labeled under code by the HMOH and shipped on dry ice to the Air Force Institute for Environment, Safety, and Occupational Health Analysis, Serum samples were stored at -20°C for 2 weeks, thawed, maintained at 4'C for 72 hours during nucleic acid extractions and blind validation testing with RT-PCR assays, and archived at -20°C. Before RT-PCR analyses, each serum sample had undergone at least two freeze-thaw cycles. The duration of exposure of the specimens to ambient temperatures throughout collection, processing, serological analyses, and preparation for shipping is unknown.
RNA Preparation
Individual mosquitoes and mosquito pools were homogenized in 500 ,uL and 1.000 /xL of TRIzol (Life Technologies), respectively, with sterile. RNase-free pestles and 1,5-mL tubes, ho- 
All patient samples were collected during the acute febrile phase.
mogenates were cleared by centrifugation in a tabletop centrifuge at 12,000 rpm for 60 seconds, and total nucleic acid extracts were prepared according to the manufacturer's instructions. Each extract was suspended in 100 p.L of RNase-free. PCR grade water with 2 U of RNase inhibitor. Human serum specimens were thawed at 4°C, and 140 pL of each specimen were suspended in 560 fiL of the buffer AVL/ carrier RNA component of a preformatted, total nucleic acid extraction kit (QlAamp viral RNA mini kit. Qiagen. Valencia, California). Extracts were prepared and suspended in 60 pL of elution buffer with the manufacturer's centrifugation protocol.
Reaction Conditions
Preliminary' assay optimizations and cross-reaction testing were conducted with a laboratory-based, real-time thermocycler. the LightCycler (Idaho Technology. Salt Lake City.
with Preformatted reagents [Titan one-tube RT-PCR kit. Roche Molecular Biochemicals, Indianapolis. Indiana). Assays were reoptimized for the Ruggedized Advanced Pathogen Identification Device (R,A,P,I.D.) (Idaho Technology) with a proprietary buffer system (Idaho Technology), and sensitivity and specificity validation testing was completed.
Master mixture reaction solution was prepared. 18'/,tL volumes were dispensed into optical capillary tubes, and 2 ^iL of RNA extract from specimens and control samples were added (or 2 ,uL of PCR-grade water for no-template control samples). Capillaries were placed in a tabletop centrifuge and centrifuged for 10 seconds at 3,000 rpm, to drive the assay mixture to the bottom of the tube. A standardized RT-PCR thermal cycling protocol was established, consisting of RT at 40T for 30 minutes followed by initial cDNA denaturation al 94''C for 2 minutes and PCR for 45 cycles of 94''C for 0 seconds for template denaturation and 60^C for 20 seconds for combined annealing and primer extension. A single data point at the end of each annealing-extension cycle was collected and reported as TaqMan probe fluorescence released by 5'-nuclease activit>' during primer extension. Fluorimeter gains were set at 8, 2, and 2 for channels 1. 2. and 3, respectively. Protocols for all five assays were identical with the exception of DEN-3, for which the extension temperature was 66X. The criterion for a positive result was a significant increase in fluorescence over background levels, as defined by an algorithm provided in the R.A.P.I.D analytical software [Roche Molecular Biochemicals).
Results
Assay Sensitivity and Specificity Testing with Flavivinis Reference Strains
Preliminary assay sensitivity and specificity evaluations were conducted with a knoun panel of total nucleic acid extracts from dengue serotype 1 -to 4-infected A. aegypti inoculated with three different strains of dengue 1. eight strains of dengue 2. three strains of dengue 3. and three strains of dengue 4 and a crossreactivity test panel consisting of totai nucleic acid extracts from multiple strains of other Flaviviridae [three strains each of yellow fever. Japanese encephalitis, and West Nile and four strains of St. Louis encephalitis). In \itro sensitivity and specificity of each assay were 100% concordant. No cross-reactivity was observed with vector species [data not shown).
Assay Sensitivity and Specificity Testing with Mosquito Panels
Testing of assay in vitro sensitivity and specificity was accomplished with a blind panel of 27 dengue-infected mosquitoes [six dengue 1-infected mosquitoes, five dengue 2. 10 dengue 3. and six dengue 4). 21 non-dengue-infected mosquitoes [seven yellow fever virus-infected A. aegypti and seven each of West Nile and St. Ix>uis encephalitis virus-infected Cufex spp.). and 11 uninfected mosquitoes, with 27 positive control samples and 32 negative control samples [ Table I ). Diluent samples were not included in statistical analyses. In the case of serotype-specific assay analyses, heterologous serotypes were considered as negative specimens. Assay results were as follows: DU-JCM, sensitivity of 100% [27 of 27 samples) and specificity of 94% Table II ). Dengue virus universal assay in vitro sensitivity was 100% [eight of eight samples) and specificity was 100% (31 of 31 samples). DEN-2 assay in vitro sensitivity was 88% (seven of eight samples) when tested against the human serum panel, with one false-negative result, and specificity was 100% [31 of 31 samples) when tested against non-dengueinfected specimens. Dengue 1, 3. and 4 assays displayed no cross-reactivity with dengue 2 serotype. Nucleic acid integrity of the human serum samples presented an unknown variable because of a lack of history regarding collection conditions, transportation and storage temperatures, and number of freeze-thaw cycles. Human genomic DNA displayed no detectable fiuorescence above background levels. Sample processing and realtime RT-PCR required <2 hours.
Discussion
We have described a rapid, sensitive, specific dengue virus RT-PCR assay system for screening and serotype identification of infected mosquito vectors and human sera. The augmentation of traditional laboratory-based testing with field-deployable RT-FCR can enhance dengue virus surveillance capability and provides a promising aid in rapid clinical laboratory diagnostics in fixed-site and deployed medical locales.
Development of pathogen identification assays with field-durable instrumentation fulfills a fundamental requirement in the realization of a complete field-deployable assay platform. Although the R,A.P.1.D provides field-deployable. real-time PCR instrumentation, an omnipotent, field-deployable. assay platform requires additional components, including thermostable assay reagents and control nucleic acid, and field-formatted sample preservation and nucleic acid isolation technologies. Therefore, in 2001, the Department of Defense established the Joint Biological Agent Identification and Diagnostic System program to develop a complete field-ready system for rapid medical surveillance and diagnostic testing at fixed-site and deployed locations.'"'The system and components (protocols and assays) will be cleared by the Food and Drug Administration for patient care use. Our experiences described below emphasize the need for a standardized system approach.
Sun'eillance studies conducted under austere conditions present logistical and operational constraints that make it impractical to transport, store, and prepare PCR reagents and control nucleic acid. Where resources for cold chain mainte-nance are unreliable or nonexistent, unknown variables in enzymatic activit}' and control nucleic acid integrity result. Moreover, sample integrity comes into question when sample collections are made distant to the laboratory or support facilities, Exposure to ambient temperature and freeze-thaw occurrences during transportation often present unknown variables in nucleic acid integrity of the sample. Also, nucleic acid extraetlon and preservation reagents designated as hazardous materials present logistical constraints because of transportation and shipping restrictions, To meet logistical and operational constraints, we have focused most intensely on the most vulnerable components of the field-deployable assay platform, namely, PCR enzymes and control nucleic acid template. The inherent fragilit\' of RNA makes maintaining RT-PCR target template integrity an especially daunting task. To ensure the validit}' of field-formatted assays, we are integrating thermostable, hydrolytic enzyme-shielded. Armored RNA control template (Ambion RNA Diagnostics, Austin. Texas) and lyophilized master mixture reagents (Idaho Technology) into our research protocols. These products proWde master mixture reagents and positive control samples that are easily transported, are field-sustainable, and require only hydration and addition of sample template for analyses. In addition to the value of Armored RNA in meeting logistical and operational constraints, there is also promise for development of quantitative \1ral assays." Our preliminary laboratory evaluation of commercial, pre formatted, thermostable, nucleic acid isolation reagents has shown promise for improved field-collected sample processing as well as sample stabilization, particularly for RNA-based viruses, Therefore, the lessons learned from this study and subsequent studies, along with probe information and protocols, wili be provided to the Joint Program Executive Office for Chemical and Biological Defense, as stipulated in the Critical Reagents Program multilaboratory agreement. Under this agreement, information and materials provided by government laboratories are evaluated for use in development of assays, protocols, and procedures for joint efforts, including the Joint Biological Agent Identification and Diagnostic System program (unpublished data).
In summaiy. this article illustrates the potential operational utility of using dengue virus assays for rapid, sensitive, and specific screening and serotype identification in mosquito vectors and human sera, on field-deployable instrumentation. This system also shows promise for development into a fully deployable package for epidemiological sur\^eiilance of dengue \1rus and a field-expedient method to augment traditional clinical laboratory diagnostic techniques. 
The road is
